The British Journal of Radiology, Vol 70, Issue 833 452-458, Copyright © 1997 by British Institute of Radiology

ARTICLES

MRI of breast cancer: influence of chemotherapy on sensitivity

A Rieber, H Zeitler, H Rosenthal, J Gorich, R Kreienberg, HJ Brambs and R Tomczak
Department of Diagnostic Radiology, University of Ulm, Germany.

MR mammography (MRM) seems to be a sensitive method for detection of breast cancer. The effect of cytotoxic agents on the dynamics of contrast medium uptake in primary breast carcinoma or recurrent disease is not known. This study addresses this question and evaluates MRM as a method of monitoring therapeutic success. A total of 13 patients (age range 34-62 years) with histologically confirmed breast cancer were investigated. The patients received neoadjuvant intravenous (iv) chemotherapy. MRM and interpretation of the dynamic measurements were performed in a standardized manner after positioning the patient in a double breast coil. A gradient echo sequence (Flash 3D, TE 5 ms, TR 12 ms, flip angle 25 degrees) was acquired before and 1, 2, 3 and 8 min after intravenous injection of Gd-DTPA 0.15 mmol kg-1 body weight. A T2 weighted SE sequence (TE 103 ms, TR 6900 ms, 4 mm, field of view 350 mm) was also obtained. MRM was performed prior to histological evaluation and after chemotherapy. All cases of malignancy were correctly diagnosed with MRM. Based on MR findings, eight patients were classified as "responders" and the remaining as "non-responders". In the "responders" a flattening of the Gd-DTPA uptake curve after the first cycle of chemotherapy of complete absence of Gd-DTPA uptake after the fourth cycle was observed. The change in Gd-DTPA uptake behaviour led to an underestimation of the extent of tumour in two patients and false negative findings in four patients. MRM provides information regarding response to therapy following the first cycle. MRM does not provide information regarding invasive tumour tissue in "responders".

This article has been cited by other articles:

				Z. Medarova, L. Rashkovetsky, P. Pantazopoulos, and A. Moore Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging Cancer Res., February 1, 2009; 69(3): 1182 - 1189. [Abstract] [Full Text] [PDF]

				C. E. Loo, H. J. Teertstra, S. Rodenhuis, M. J. van de Vijver, J. Hannemann, S. H. Muller, M.-J. V. Peeters, and K. G. A. Gilhuijs Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results Am. J. Roentgenol., November 1, 2008; 191(5): 1331 - 1338. [Abstract] [Full Text] [PDF]

				C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]

				S. C. Partridge, J. E. Gibbs, Y. Lu, L. J. Esserman, D. Tripathy, D. S. Wolverton, H. S. Rugo, E. S. Hwang, C. A. Ewing, and N. M. Hylton MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival Am. J. Roentgenol., June 1, 2005; 184(6): 1774 - 1781. [Abstract] [Full Text] [PDF]

				C. El Khoury, V. Servois, F. Thibault, A. Tardivon, L. Ollivier, M. Meunier, C. Allonier, and S. Neuenschwander MR Quantification of the Washout Changes in Breast Tumors Under Preoperative Chemotherapy: Feasibility and Preliminary Results Am. J. Roentgenol., May 1, 2005; 184(5): 1499 - 1504. [Abstract] [Full Text] [PDF]

				M. Koomen, E. D. Pisano, C. Kuzmiak, D. Pavic, and R. McLelland Future Directions in Breast Imaging J. Clin. Oncol., March 10, 2005; 23(8): 1674 - 1677. [Full Text] [PDF]

				F. Thibault, C. Nos, M. Meunier, C. El Khoury, L. Ollivier, B. Sigal-Zafrani, and K. Clough MRI for Surgical Planning in Patients with Breast Cancer Who Undergo Preoperative Chemotherapy Am. J. Roentgenol., October 1, 2004; 183(4): 1159 - 1168. [Abstract] [Full Text] [PDF]

				S. H. Giordano Update on Locally Advanced Breast Cancer Oncologist, December 1, 2003; 8(6): 521 - 530. [Abstract] [Full Text] [PDF]

				N. Morakkabati, C. C. Leutner, A. Schmiedel, H. H. Schild, and C. K. Kuhl Breast MR Imaging during or Soon after Radiation Therapy Radiology, December 1, 2003; 229(3): 893 - 901. [Abstract] [Full Text] [PDF]

				E. L. Rosen, K. L. Blackwell, J. A. Baker, M. S. Soo, R. C. Bentley, D. Yu, T. V. Samulski, and M. W. Dewhirst Accuracy of MRI in the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy Am. J. Roentgenol., November 1, 2003; 181(5): 1275 - 1282. [Abstract] [Full Text] [PDF]

				S. C. Partridge, J. E. Gibbs, Y. Lu, L. J. Esserman, D. Sudilovsky, and N. M. Hylton Accuracy of MR Imaging for Revealing Residual Breast Cancer in Patients Who Have Undergone Neoadjuvant Chemotherapy Am. J. Roentgenol., November 1, 2002; 179(5): 1193 - 1199. [Abstract] [Full Text] [PDF]

				S. C. A. Michel, T. M. Keller, J. M. Frohlich, D. Fink, R. Caduff, B. Seifert, B. Marincek, and R. A. Kubik-Huch Preoperative Breast Cancer Staging: MR Imaging of the Axilla with Ultrasmall Superparamagnetic Iron Oxide Enhancement Radiology, November 1, 2002; 225(2): 527 - 536. [Abstract] [Full Text] [PDF]

				L. Esserman, E. Kaplan, S. Partridge, D. Tripathy, H. Rugo, J. Park, S. Hwang, H. Kuerer, D. Sudilovsky, Y. Lu, et al. MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer Ann. Surg. Oncol., July 1, 2001; 8(6): 549 - 559. [Abstract] [Full Text] [PDF]

				S. G. Orel and M. D. Schnall MR Imaging of the Breast for the Detection, Diagnosis, and Staging of Breast Cancer Radiology, July 1, 2001; 220(1): 13 - 30. [Abstract] [Full Text] [PDF]

				I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]